{
  "_originalData": {
    "identity": {
      "bacteriumName": "Campylobacter jejuni / coli",
      "aliases": [
        "Campylobacter jejuni",
        "Campylobacter coli"
      ],
      "lastUpdated": "2025-04-22",
      "clsiCategory": "Other Non-Enterobacterales",
      "classification": {
        "gramStain": "Gram-negative",
        "morphology": "Rod (gull-wing appearance)",
        "respiration": "Microaerophilic",
        "notes": []
      },
      "strainDetails": [
        {
          "type": "Species",
          "value": "Campylobacter jejuni",
          "notes": "Accounts for 85% or more of cases."
        },
        {
          "type": "Species",
          "value": "Campylobacter coli",
          "notes": ""
        }
      ],
      "biochemicalTests": "Gram-negative, curved or S-shaped (gull-wing) rods, microaerophilic, grows at 42°C, oxidase +, catalase +, motile (single polar flagellum), hippurate hydrolysis + (C. jejuni) or – (C. coli)."
    },
    "clinicalProfile": {
      "summary": "Campylobacter jejuni and C. coli are leading causes of acute bacterial gastroenteritis worldwide. The illness is typically self-limited, but treatment is recommended for severe or prolonged cases, and in high-risk individuals.",
      "pathophysiologyPearls": [
        "Infection is primarily foodborne, often from contaminated poultry.",
        "The abdominal pain can be severe enough to mimic appendicitis."
      ],
      "keySignsAndSymptoms": [
        "Diarrhea (often bloody)",
        "Abdominal pain and cramping",
        "Fever",
        "Nausea and vomiting",
        "Headache and myalgia"
      ],
      "clinicalSyndromes": [
        {
          "syndromeName": "Gastroenteritis",
          "description": "The most common presentation, characterized by acute diarrhea."
        },
        {
          "syndromeName": "Guillain-Barré Syndrome",
          "description": "A post-infectious complication, with Campylobacter being the most common infectious precipitant."
        },
        {
          "syndromeName": "Reactive Arthritis",
          "description": "A potential post-infectious sequela."
        },
        {
          "syndromeName": "Irritable Bowel Syndrome",
          "description": "Can be triggered by Campylobacter infection."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Children under 5",
        "Elderly (65 years and older)",
        "Pregnant women",
        "Immunocompromised patients",
        "Travelers"
      ],
      "transmissionVectors": [
        "Contaminated food (especially poultry)",
        "Contaminated water"
      ],
      "prognosisNotes": [
        "Antimicrobial therapy typically shortens the duration of symptoms by about one day."
      ]
    },
    "resistanceProfile": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [
        {
          "drugOrClass": "TMP-SMX",
          "notes": "Not active against Campylobacter."
        },
        {
          "drugOrClass": "Penicillins",
          "notes": "Not active against Campylobacter."
        },
        {
          "drugOrClass": "Cephalosporins",
          "notes": "Not active against Campylobacter."
        }
      ],
      "majorMechanisms": [],
      "clinicalAlerts": [
        {
          "alertTitle": "Widespread Fluoroquinolone Resistance",
          "details": "Resistance to fluoroquinolones is common, particularly in strains from outside the US. Susceptibility testing is necessary for serious infections."
        },
        {
          "alertTitle": "Increasing Macrolide Resistance",
          "details": "Resistance to macrolides, the first-line agents, is emerging, especially in certain geographic regions and in children in under-resourced settings."
        }
      ]
    },
    "treatment": {
      "generalNotes": [
        "Treatment is recommended for patients with prolonged or severe disease (e.g., fever, bloody stools) and for immunocompromised patients.",
        "For severe, life-threatening infections, consider an aminoglycoside or a carbapenem.",
        "Azithromycin is the drug of choice for traveler's diarrhea caused by Campylobacter due to high rates of fluoroquinolone resistance."
      ],
      "drugsToAvoid": [],
      "adjunctiveTherapies": [],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "condition": "Gastroenteritis",
            "patientPopulation": [
              "Adults with severe or prolonged disease",
              "Immunocompromised patients"
            ],
            "isolateSource": "Stool"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "3 days",
                  "drugs": [
                    {
                      "drugName": "Azithromycin",
                      "dose": "500",
                      "route": "IV/PO",
                      "frequency": "q24h",
                      "comments": "If bacteremic (rare), treat for 14 days."
                    }
                  ]
                },
                {
                  "step": 1,
                  "duration": "1 day",
                  "drugs": [
                    {
                      "drugName": "Azithromycin",
                      "dose": "1000",
                      "route": "PO",
                      "frequency": "once",
                      "comments": "For mild, non-bacteremic disease."
                    }
                  ]
                }
              ],
              "notes": []
            },
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "5 days",
                  "drugs": [
                    {
                      "drugName": "Ciprofloxacin",
                      "dose": "500",
                      "route": "PO",
                      "frequency": "BID",
                      "comments": "Confirm susceptibility due to common resistance."
                    }
                  ]
                },
                {
                  "step": 1,
                  "duration": "3 days",
                  "drugs": [
                    {
                      "drugName": "Erythromycin",
                      "dose": "500",
                      "route": "PO",
                      "frequency": "QID",
                      "comments": ""
                    }
                  ]
                },
                {
                  "step": 1,
                  "duration": "5 days",
                  "drugs": [
                    {
                      "drugName": "Doxycycline",
                      "dose": "100",
                      "route": "PO",
                      "frequency": "BID",
                      "comments": "Confirm susceptibility due to common resistance."
                    }
                  ]
                }
              ],
              "notes": [
                "Consider Amoxicillin-clavulanate as an alternative for children in under-resourced settings with high resistance rates."
              ]
            }
          ]
        }
      ]
    },
    "laboratoryProfile": {
      "testingIndications": [
        "Stool culture on selective media is required for diagnosis.",
        "Susceptibility testing should be performed for severe infections or when treatment failure occurs."
      ],
      "methodologyNotes": [],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    },
    "additionalInformation": {
      "diagnosticNotes": {
        "summary": "",
        "biosafetyWarning": "",
        "methods": []
      },
      "preventionAndScreening": [],
      "treatmentLifecycle": [],
      "antimicrobialStewardship": [],
      "drugSpecificPearls": [],
      "guidelineReferences": [
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis 44:696, 2007",
          "summaryOrNote": "Review on the modest benefit of antimicrobial therapy."
        },
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis 44:701, 2007",
          "summaryOrNote": "Information on the epidemiology of Campylobacter infection."
        },
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis 57: 1600, 2013",
          "summaryOrNote": "Information on the epidemiology of Campylobacter infection."
        },
        {
          "source": "New England Journal of Medicine",
          "citation": "N Engl J Med 366: 2294, 2012",
          "summaryOrNote": "Information on post-infectious complications."
        },
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis 2022; 75:702",
          "summaryOrNote": "Observational trial on antimicrobial resistance in France."
        },
        {
          "source": "Antimicrobial Agents and Chemotherapy",
          "citation": "Antimicrob Agents Chemother 54:1232, 2010",
          "summaryOrNote": "Information on azithromycin for traveler's diarrhea."
        },
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis 48:1500, 2009",
          "summaryOrNote": "Information on azithromycin for traveler's diarrhea."
        },
        {
          "source": "The Lancet Global Health",
          "citation": "Lancet Glob Health 2018:e1309",
          "summaryOrNote": "Information on Campylobacter in children in under-resourced settings."
        },
        {
          "source": "The Lancet",
          "citation": "Lancet 2016 388:1291",
          "summaryOrNote": "Information on Campylobacter in children in under-resourced settings."
        },
        {
          "source": "Antimicrobial Agents and Chemotherapy",
          "citation": "Antimicrob Agents Chemother 2018 Nov 12. pii: AAC.01911-18",
          "summaryOrNote": "Information on antimicrobial resistance in children in under-resourced settings."
        },
        {
          "source": "Infectious Diseases Society of America (IDSA)",
          "citation": "Clin Infect Dis 65: e65, 2017",
          "summaryOrNote": "2017 IDSA Guidelines for the Diagnosis and Management of Infectious Diarrhea."
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "laboratoryProfile",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.326Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Campylobacter jejuni / coli"
    },
    "aliases": {
      "sources": [
        "identity.aliases"
      ],
      "value": [
        "Campylobacter jejuni",
        "Campylobacter coli"
      ]
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2025-04-22"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram-negative",
        "morphology": "Rod (gull-wing appearance)",
        "respiration": "Microaerophilic",
        "notes": []
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Campylobacter jejuni and C. coli are leading causes of acute bacterial gastroenteritis worldwide. The illness is typically self-limited, but treatment is recommended for severe or prolonged cases, and in high-risk individuals.",
      "pathophysiologyPearls": [
        "Infection is primarily foodborne, often from contaminated poultry.",
        "The abdominal pain can be severe enough to mimic appendicitis."
      ],
      "keySignsAndSymptoms": [
        "Diarrhea (often bloody)",
        "Abdominal pain and cramping",
        "Fever",
        "Nausea and vomiting",
        "Headache and myalgia"
      ],
      "clinicalSyndromes": [
        {
          "syndromeName": "Gastroenteritis",
          "description": "The most common presentation, characterized by acute diarrhea."
        },
        {
          "syndromeName": "Guillain-Barré Syndrome",
          "description": "A post-infectious complication, with Campylobacter being the most common infectious precipitant."
        },
        {
          "syndromeName": "Reactive Arthritis",
          "description": "A potential post-infectious sequela."
        },
        {
          "syndromeName": "Irritable Bowel Syndrome",
          "description": "Can be triggered by Campylobacter infection."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Children under 5",
        "Elderly (65 years and older)",
        "Pregnant women",
        "Immunocompromised patients",
        "Travelers"
      ],
      "transmissionVectors": [
        "Contaminated food (especially poultry)",
        "Contaminated water"
      ],
      "prognosisNotes": [
        "Antimicrobial therapy typically shortens the duration of symptoms by about one day."
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [
        {
          "drugOrClass": "TMP-SMX",
          "notes": "Not active against Campylobacter."
        },
        {
          "drugOrClass": "Penicillins",
          "notes": "Not active against Campylobacter."
        },
        {
          "drugOrClass": "Cephalosporins",
          "notes": "Not active against Campylobacter."
        }
      ],
      "majorMechanisms": [],
      "clinicalAlerts": [
        {
          "alertTitle": "Widespread Fluoroquinolone Resistance",
          "details": "Resistance to fluoroquinolones is common, particularly in strains from outside the US. Susceptibility testing is necessary for serious infections."
        },
        {
          "alertTitle": "Increasing Macrolide Resistance",
          "details": "Resistance to macrolides, the first-line agents, is emerging, especially in certain geographic regions and in children in under-resourced settings."
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": [
        {
          "regimenId": "modern-0-0-0",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Gastroenteritis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults with severe or prolonged disease",
                "Immunocompromised patients"
              ],
              "labFindings": "Stool"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Azithromycin",
              "dose": "500",
              "route": "IV/PO",
              "frequency": "q24h",
              "duration": "3 days",
              "comments": "If bacteremic (rare), treat for 14 days.",
              "originalText": "Azithromycin 500 IV/PO q24h"
            }
          ]
        },
        {
          "regimenId": "modern-0-0-1",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[1]",
          "context": {
            "type": "directed",
            "condition": "Gastroenteritis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults with severe or prolonged disease",
                "Immunocompromised patients"
              ],
              "labFindings": "Stool"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Azithromycin",
              "dose": "1000",
              "route": "PO",
              "frequency": "once",
              "duration": "1 day",
              "comments": "For mild, non-bacteremic disease.",
              "originalText": "Azithromycin 1000 PO once"
            }
          ]
        },
        {
          "regimenId": "modern-0-1-0",
          "extractedFrom": "treatment.regimens[0].recommendations[1].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Gastroenteritis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults with severe or prolonged disease",
                "Immunocompromised patients"
              ],
              "labFindings": "Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Ciprofloxacin",
              "dose": "500",
              "route": "PO",
              "frequency": "BID",
              "duration": "5 days",
              "comments": "Confirm susceptibility due to common resistance.",
              "originalText": "Ciprofloxacin 500 PO BID"
            }
          ]
        },
        {
          "regimenId": "modern-0-1-1",
          "extractedFrom": "treatment.regimens[0].recommendations[1].steps[1]",
          "context": {
            "type": "directed",
            "condition": "Gastroenteritis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults with severe or prolonged disease",
                "Immunocompromised patients"
              ],
              "labFindings": "Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Erythromycin",
              "dose": "500",
              "route": "PO",
              "frequency": "QID",
              "duration": "3 days",
              "comments": "",
              "originalText": "Erythromycin 500 PO QID"
            }
          ]
        },
        {
          "regimenId": "modern-0-1-2",
          "extractedFrom": "treatment.regimens[0].recommendations[1].steps[2]",
          "context": {
            "type": "directed",
            "condition": "Gastroenteritis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults with severe or prolonged disease",
                "Immunocompromised patients"
              ],
              "labFindings": "Stool"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Doxycycline",
              "dose": "100",
              "route": "PO",
              "frequency": "BID",
              "duration": "5 days",
              "comments": "Confirm susceptibility due to common resistance.",
              "originalText": "Doxycycline 100 PO BID"
            }
          ]
        }
      ]
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile"
    ],
    "value": {
      "testingIndications": [
        "Stool culture on selective media is required for diagnosis.",
        "Susceptibility testing should be performed for severe infections or when treatment failure occurs."
      ],
      "methodologyNotes": [],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}